Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer
Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.